Want to see HK:1244 full AI Analyst Report?
1244 Stock Chart & Stats
HK$6.14
-HK$0.10(-2.80%)
At close: 4:00 PM EST
HK$6.14
-HK$0.10(-2.80%)
Day’s Range― - ―
52-Week RangeHK$2.09 - HK$10.02
Previous CloseN/A
Volume120.00K
Average Volume (3M)393.13K
Market Cap
HK$593.81M
Enterprise ValueHK$605.77M
Total Cash (Recent Filing)HK$438.10M
Total Debt (Recent Filing)HK$152.85M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding258,177,000
10 Day Avg. Volume535,000
30 Day Avg. Volume393,126
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~92% gross margin in 2025 signals durable product-level profitability and pricing power in core oncology offerings. High gross margins provide structural capacity to fund R&D and commercialization if revenue stabilizes, buffering operating leverage and improving long-term unit economics.
Manageable LeverageLeverage at ~0.26 indicates the company is not heavily debt-funded, preserving financial flexibility for clinical programs or business development. Reduced leverage versus prior years lowers refinancing risk and supports survival through cash burn periods without excessive interest burdens.
Improving Cash BurnTrend of reduced cash burn versus 2024 suggests management is improving cost discipline or product mix, which is a durable operational improvement. Gradual burn reduction increases runway and reduces reliance on dilutive financing, supporting medium-term viability of clinical programs.
Bears Say
Persistent Negative FCFConsistent negative operating and free cash flow (~-150M in 2025) is a structural weakness that forces ongoing external financing or asset draws. Persistent cash outflow constrains reinvestment, increases dilution risk, and limits ability to scale commercialization without capital markets access.
Revenue ContractionA ~23% revenue decline in 2025 reflects weakening commercial traction or market demand that undermines operating leverage. Continued top-line shrinkage can offset high gross margins, pressuring margins, reducing scale benefits, and making path to sustainable profitability more uncertain.
Ongoing Operating & Net LossesMaterial negative ROE (~-29%) and continued operating/net losses indicate the business has yet to convert high gross margins into shareholder returns. Eroding equity from repeated losses raises long-term solvency risk and may force strategic trade-offs between R&D, commercial investment, and capital raises.
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$2.09 and its highest was HK$10.02 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$593.81M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Aug 28, 2026 which is in 47 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.392 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.392.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.392 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.866%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3D Medicines, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.03%
12-Months-Change
Fundamentals
Return on Equity
-27.04%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
3D Medicines, Inc.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Technical Analysis
Alphamab Oncology
―
JW (Cayman) Therapeutics Co. Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---